GlassScriptPhysician profile
Fnu Sidra
NPI 1932694247
$2,806.86
in general payments reported to CMS, 2019-2025
30 companies · $1,148 in 2025
The $1,148 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $631 · 2024: $1,029 · 2025: $1,148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,807.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,806.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $655.11 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $296.47 | 2024-2025 | |
| Beta Bionics, INC. | $246.39 | 2023-2024 | Ilet Bionic Pancreas |
| Amgen INC. | $175.88 | 2024-2025 | Tepezza, Repatha |
| Lilly USA, LLC | $165.00 | 2023-2024 | Mounjaro, Trulicity, Zepbound |
| Dexcom, INC. | $160.47 | 2023-2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $121.44 | 2023 | Minimed 780g |
| Cequr Corporation | $113.26 | 2025 | Cequr Simplicity |
| Tandem Diabetes Care, INC. | $109.01 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Bayer Healthcare Pharmaceuticals INC. | $85.77 | 2023-2025 | |
| Amneal Pharmaceuticals LLC | $67.99 | 2023-2024 | Unithroid |
| Corcept Therapeutics | $62.87 | 2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $60.90 | 2023-2024 | |
| Insulet Corporation | $57.10 | 2023 | Omnipod |
| Abbvie INC. | $55.83 | 2023-2025 | Synthroid |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $53.50 | 2025 | Freestyle Libre |
| Ibsa Pharma INC. | $44.28 | 2024 | Licart, Tirosint |
| Madrigal Pharmaceuticals | $43.53 | 2025 | Rezdiffra |
| Xeris Pharmaceuticals, INC. | $24.78 | 2023 | Gvoke Hypopen |
| Radius Health, INC. | $24.12 | 2023 | Tymlos |
| Antares Pharma, INC. | $22.68 | 2025 | Xyosted |
| Alexion Pharmaceuticals, INC. | $22.31 | 2024 | Strensiq |
| Mannkind Corporation | $20.30 | 2024 | |
| Halozyme INC | $19.92 | 2023 | |
| Boston Scientific Corporation | $19.00 | 2024 | |
| Ascendis Pharma Endocrinology INC | $18.60 | 2025 | Yorvipath |
| Esperion Therapeutics, INC. | $17.89 | 2025 | Nexletol |
| Ionis Pharmaceuticals, INC. | $15.56 | 2025 | Tryngolza |
| Kyowa Kirin, INC. | $14.04 | 2023 | Crysvita |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.86 | 2023 | Tradjenta, Trijardy Xr, Glyxambi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fnu Sidra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.